补阳还五汤联合GP化疗方案治疗晚期非小细胞肺癌的临床效果(1)
[摘要] 目的 探讨补阳还五汤联合顺铂(GP)化疗方案治疗对晚期非小细胞肺癌(NSCLC)患者高凝状态、生活质量的影响。 方法 选取2016年8月～2018年3月东南大学附属中大医院(以下简称“我院”)收治的晚期NSCLC患者113例。采用随机数字表法将患者分为对照组56例和研究组57例，对照组患者予吉西他滨联合GP化疗方案，研究组在此基础上联合补阳还五汤治疗。比较两组临床疗效、凝血状态、生活质量，观察比较两组治疗时不良反应发生情况。 结果 研究组患者临床总有效率明显高于对照组(P < 0.05)。治疗后两组患者血小板计数(PLT)、纤维蛋白原(FIB)、凝血酶原时间(PT)以及凝血活酶时间(APTT)均较本组治疗前下降，且研究组低于对照组(P < 0.05)。治疗后两组患者卡氏(KPS)评分较本组治疗前升高(P < 0.05)，且研究组高于对照组(P < 0.01)。研究组不良反应总发生率低于对照组(P < 0.01)。 结论 补阳还五汤联合GP化疗方案治疗晚期NSCLC，疗效确切，可缓解高凝状态，并改善生活质量，且不良反应较少，安全性高。
[关键词] 补阳还五汤;顺铂化疗;晚期非小细胞肺癌;临床研究
[中图分类号] R734 [文献标识码] A [文章编号] 1673-7210(2018)12(c)-0113-04
[Abstract] Objective To investigate the effect of Buyang Huanwu Decoction combined with GP chemotherapy on hypercoagulability and quality of life in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 113 patients with NSCLC admitted to Zhongda Hospital， Southeast University from August 2016 to March 2018 were selected. The patients were divided into control group 56 cases and study group 57 cases by random number table method. The control group was given the chemotherapy regimen of Gemcitabine combined with Cisplatin (GP)， and the study group was combined with Buyang Huanwu Decoction on the basis of the control group. The clinical efficacy， coagulation state and quality of life of the two groups were compared. Adverse reactions of the two groups were observed and compared. Results The total effective rate in the study group was significantly higher than the control group (P < 0.05). After treatment， PLT， FIB， PT and APTT levels of the two groups decreased than those before treatment， and those in the study group were lower than the control group (P < 0.05). The KPS scores of the two groups increased after treatment (P < 0.05)， and that in the study group was higher than the control group (P < 0.01). The total incidence of adverse reactions in the study group was lower than the control group (P < 0.01). Conclusion The combination of Buyang Huanwu Decoction combined with GP chemotherapy is effective and reliable in the treatment of advanced NSCLC. It can relieve the hypercoagulability and improve the quality of life， with few adverse reactions and high safety.
[Key words] Buyang Huanwu Decoction; GP chemotherapy; Advanced non-small cell lung cancer; Clinical research
肺癌是最常见的原发性恶性肿瘤，主要分为小细胞肺癌和非小细胞肺癌[1]。其中非小细胞肺癌(NSCLC)约占肺癌的70%，由于NSCLC早期临床症状无特异性，因此，患者一经确诊多处于中晚期，已错过最佳手术治疗時间[2]。吉西他滨联合顺铂(GP)化疗方案是治疗晚期NSCLC的常用方法，虽然该方案具有一定的治疗效果，然而仍存在部分患者出现不能耐受、不良反应较大等问题，治疗存在一定的优化空间[3]。随着近年来中医药的发展，中西医结合治疗晚期NSCLC已被临床广泛使用[4]，既往临床观察显示，晚期NSCLC患者均存在气虚血瘀证[5]，而补阳还五汤作为气虚血瘀证的基础药方，其疗效在各类气虚血瘀证的疾病中已得到证实[6]。现临床有关补阳还五汤联合GP化疗方案治疗晚期NSCLC的研究较少，鉴于此，本研究通过探讨上述联合治疗方案对晚期NSCLC患者的影响，以期为临床治疗提供参考。, 百拇医药(武宜婷 渠景连 郭楠楠 赵峰 刘燕文)
[关键词] 补阳还五汤;顺铂化疗;晚期非小细胞肺癌;临床研究
[中图分类号] R734 [文献标识码] A [文章编号] 1673-7210(2018)12(c)-0113-04
[Abstract] Objective To investigate the effect of Buyang Huanwu Decoction combined with GP chemotherapy on hypercoagulability and quality of life in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 113 patients with NSCLC admitted to Zhongda Hospital， Southeast University from August 2016 to March 2018 were selected. The patients were divided into control group 56 cases and study group 57 cases by random number table method. The control group was given the chemotherapy regimen of Gemcitabine combined with Cisplatin (GP)， and the study group was combined with Buyang Huanwu Decoction on the basis of the control group. The clinical efficacy， coagulation state and quality of life of the two groups were compared. Adverse reactions of the two groups were observed and compared. Results The total effective rate in the study group was significantly higher than the control group (P < 0.05). After treatment， PLT， FIB， PT and APTT levels of the two groups decreased than those before treatment， and those in the study group were lower than the control group (P < 0.05). The KPS scores of the two groups increased after treatment (P < 0.05)， and that in the study group was higher than the control group (P < 0.01). The total incidence of adverse reactions in the study group was lower than the control group (P < 0.01). Conclusion The combination of Buyang Huanwu Decoction combined with GP chemotherapy is effective and reliable in the treatment of advanced NSCLC. It can relieve the hypercoagulability and improve the quality of life， with few adverse reactions and high safety.
[Key words] Buyang Huanwu Decoction; GP chemotherapy; Advanced non-small cell lung cancer; Clinical research
肺癌是最常见的原发性恶性肿瘤，主要分为小细胞肺癌和非小细胞肺癌[1]。其中非小细胞肺癌(NSCLC)约占肺癌的70%，由于NSCLC早期临床症状无特异性，因此，患者一经确诊多处于中晚期，已错过最佳手术治疗時间[2]。吉西他滨联合顺铂(GP)化疗方案是治疗晚期NSCLC的常用方法，虽然该方案具有一定的治疗效果，然而仍存在部分患者出现不能耐受、不良反应较大等问题，治疗存在一定的优化空间[3]。随着近年来中医药的发展，中西医结合治疗晚期NSCLC已被临床广泛使用[4]，既往临床观察显示，晚期NSCLC患者均存在气虚血瘀证[5]，而补阳还五汤作为气虚血瘀证的基础药方，其疗效在各类气虚血瘀证的疾病中已得到证实[6]。现临床有关补阳还五汤联合GP化疗方案治疗晚期NSCLC的研究较少，鉴于此，本研究通过探讨上述联合治疗方案对晚期NSCLC患者的影响，以期为临床治疗提供参考。, 百拇医药(武宜婷 渠景连 郭楠楠 赵峰 刘燕文)